Calming the SARS-CoV-2-induced cytokine storm with Leinco’s high-grade antibodies, proteins, and ELISAs

Since March 2020, scientists and researchers have spent countless hours studying SARS-CoV-2, the virus that caused the coronavirus disease 2019 (COVID-19) pandemic. One big topic and mystery to many is why COVID-19 causes mild disease and symptoms in most people, but turns extreme and often fatal for others?

Studies have shown that COVID-19 patients exhibit an immune response called Cytokine Storm - also referred to as cytokine storm syndrome (CSS), cytokine release syndrome (CRS), hypercytokinemia, macrophage activation syndrome - resulting in the immune system spinning out of control. CRS occurs when the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules known as cytokines. Many studies have shown that severely ill patients tend to have a higher concentration of pro-inflammatory cytokines than those moderately ill COVID-19 patients.

The study of CRS has become increasingly important in exploring potential therapeutic treatment options for coronavirus patients, as well as anyone battling a serious infection, to minimize Intensive Care Unit (ICU) patient visits and ultimately improving survival rates. Although there is insufficient evidence supporting the regulation of Cytokine Storm and COVID-19 mortality rates, research and clinical trials are ongoing.

Monitor cytokine storm with Leinco Technologies’ research reagents

Leinco Technologies is committed to providing necessary tools to researchers as they investigate and discover critical new information on COVID-19 and Cytokine Storm detection and prevention.

Download this interactive PDF to explore Leinco's products for SARS-CoV-2 and cytokine research >>

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>